key: cord-0952615-h7zx9cr3
authors: Kimura, Izumi; Kosugi, Yusuke; Wu, Jiaqi; Zahradnik, Jiri; Yamasoba, Daichi; Butlertanaka, Erika P.; Tanaka, Yuri L.; Uriu, Keiya; Liu, Yafei; Morizako, Nanami; Shirakawa, Kotaro; Kazuma, Yasuhiro; Nomura, Ryosuke; Horisawa, Yoshihito; Tokunaga, Kenzo; Ueno, Takamasa; Takaori-Kondo, Akifumi; Schreiber, Gideon; Arase, Hisashi; Motozono, Chihiro; Saito, Akatsuki; Nakagawa, So; Sato, Kei
title: The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance
date: 2021-12-18
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.110218
sha: 33561d75a8b8ecea12ee3a742907752fcabadaf1
doc_id: 952615
cord_uid: h7zx9cr3

SARS-CoV-2 Lambda, a variant of interest, has spread in some South American countries; however, its virological features and evolutionary traits remain unknown. In this study, we use pseudoviruses and reveal that the spike protein of the Lambda variant is more infectious than that of other variants due to the T76I and L452Q mutations. The RSYLTPGD246-253N mutation, a unique 7-amino-acid deletion in the N-terminal domain of the Lambda spike protein, is responsible for evasion from neutralizing antibodies and further augments antibody-mediated enhancement of infection. Although this mutation generates a nascent N-linked glycosylation site, the additional N-linked glycan is dispensable for the virological property conferred by this mutation. Since the Lambda variant has dominantly spread according to the increasing frequency of the isolates harboring the RSYLTPGD246-253N mutation, our data suggest that the RSYLTPGD246-253N mutation is closely associated with the substantial spread of the Lambda variant in South America.

further demonstrated that the RSYLTPGD246-253N mutation, a unique mutation in 107 the NTD of the Lambda S protein, is responsible for the virological phenotype of the 108

Lambda variant that is associated with the major infectious spread mainly in South 109

American countries. 110 J o u r n a l P r e -p r o o f

Epidemic dynamics of the Lambda variant in South American countries 112

As of June 29, 2021, 1,908 genome sequences of the Lambda variant belonging to 113 the PANGO C.37 lineage have been isolated from 26 countries and deposited in 114 GISAID. Although the Lambda variant was first reported in Peru in December 2020 115 (WHO, 2021a), our in-depth analysis revealed that this variant was first detected in 116

Argentina on November 8, 2020 (GISAID ID: EPI_ISL_2158693) ( Figure 1A ; see 117 STAR★METHODS for details). The prevalence of the Lambda variant is increasing 118

in South American countries, including Peru, Chile, and Argentina ( Figure 1A and 119 Table S1 ), suggesting that this variant is spreading predominantly in these countries 120 ( Table S2) . We then generated a maximum likelihood-based phylogenetic tree of 121 the Lambda variant ( Figure S1A ). Although there were some isolates that were 122 misclassified as Lambda, which could be the "sister group of Lambda variants", our 123 phylogenetic tree indicated the monophyly of the "genuine Lambda variants" isolates 124 ( Figure S1A ).

Association of the Lambda variant spread with the increasing frequency of 127

isolates harboring the RSYLTPGD246-253N mutation 128

In the 1,908 sequences of the Lambda variant (C.37 lineage), the majority of the S 129 protein sequence of the "genuine Lambda variants" contains six substitution 130 mutations (G75V, T76I, L452Q, F490S, D614G and T859N) and a 7-amino-acid 131 deletion in the NTD (RSYLTPGD246-253N) ( Figure S1A) . Indeed, the Lambda 132 variant first isolated in Argentina (GISAID ID: EPI_ISL_2158693) contains the six 133 amino acid mutations as well as the deletion in the S protein. On the other hand, the 134 "sister group of Lambda variants" does not contain any of the seven mutations 135 excluding D614G in their S proteins ( Figure S1A ). 136 We then analyzed the mutations in the S protein using the 1,908 sequences 137 of the Lambda variant (C.37 lineage) and showed that the six amino acid mutations 138 are highly (> 90%) conserved (Figures 1B) . Although a large deletion in the NTD, 139 the RSYLTPGD246-253N mutation, is also highly conserved and only 287 of the 140 1,908 sequences (15.0%) of the Lambda variant (C.37 lineage) genomes do not 141 harbor this mutation (Figures 1B and S1A) . To determine whether the epidemic 142 dynamic of the Lambda variant is associated with the emergence of the 143 RSYLTPGD246-253N mutation, we examined all amino acid changes in the S 144 protein of the SARS-CoV-2 genomes deposited in the GISAID database (2,084,604 145 sequences; as of June 29, 2021). Our analysis showed that the RSYLTPGD246-146

253N mutation was first found in Argentina on November 8, 2020 (GISAID ID:  147 EPI_ISL_2158693), which is the first isolate of the Lambda variant ( Figure 1A) , 148 J o u r n a l P r e -p r o o f suggesting that this deletion event uniquely occurred in the ancestral lineage of the 149 "genuine Lambda variants". We then analyzed the molecular evolutionary dynamics 150 of the Lambda variants by performing Bayesian tip-dating analysis. We showed that 151 the estimated time to the most recent common ancestor of the "genuine Lambda 152

variants" was around July 12, 2020 [95% highest posterior density (HPD), January 153 5, 2020-October 22, 2020] (Figures 1C and S1B) . To infer the population dynamics 154 of the lineage, we performed a Bayesian skyline plot analysis. This analysis showed 155 that the effective population size of the Lambda variant increased at the beginning 156 of 2021 ( Figure 1D) . Intriguingly, when we plotted the proportion of the Lambda 157 variant with the RSYLTPGD246-253N mutation, we found that it was increased after 158 the emergence of the Lambda variant and closely associated with the increase in 159 effective population size ( Figure 1D ). These results suggest that the acquisition of 160 the RSYLTPGD246-253N mutation is associated with the outbreak of the Lambda 161 variant in South America. 162 163

Enhanced infectivity and resistance to NAbs of the Lambda variant 164

To address the virological phenotype of the Lambda variant (hereafter, only "genuine 165

Lambda variant" are referred to as "Lambda variant"), we prepared viruses 166 pseudotyped with the S proteins of the Lambda variant as well as four VOCs, Alpha 167 (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) ( Figure S1C ). We also 168 prepared pseudoviruses with the S protein of the Epsilon (B.1.427/429) variant 169 ( Figure S1C) , which was used to be a VOC/VOI and was reclassified on July 6, 2021 170 (WHO, 2021a). As the control of this experiment, the pseudoviruses with the S 171 protein of the D614G-bearing isolate (B.1 lineage), which has spread in the early 172 pandemic (i.e., during early 2020 and before the emergence of VOCs/VOIs) (Ozono 173 et al., 2021), was prepared, and this is referred to as "parental virus" in this study. 174

As shown in Figure 2A , Beta variants were lower than that of the parental virus (Figure 2A) . However, the 182 lower infectivity of the Alpha variant compared to the D614G-bearing early pandemic 183 virus, analyzed by pseudovirus assay (Figure 2A) , is consistent with a previous 184 report (Acevedo et al., 2021) . In contrast, the infectivities of the Delta, Epsilon and 185

Lambda variants were significantly higher than that of the parental virus (Figure 2A : 186 J o u r n a l P r e -p r o o f P = 0.017, Delta versus parental; P = 0.0031, Epsilon versus parental; P = 0.0004, 187

Lambda versus parental by Student's t test). This pattern was independent of the 188 input dose of pseudoviruses used ( Figure S2B ).

To assess the effect of a characteristic mutation of the Lambda variant, the 190 RSYLTPGD246-253N mutation (Figure 1) , on viral infectivity, we prepared a 191 pseudovirus with the Lambda S derivative with the recovery of this deletion 192 ("Lambda+N246-253RSYLTPGD") ( Figure S2A ). The infectivity of this mutant was 193 comparable to that of the Lambda S (Figures 2A and S2B induced by BNT162b2 vaccination ( Table S4) . As shown in Figure 2B , Lambda S 203 was, on average, 1.5-fold (2.63-fold at a maximum) more resistant to induced antisera than the parental S (P = 0.0077 by the Wilcoxon matched-pairs 205 signed rank test). However, the neutralization level of Lambda+N246-206

253RSYLTPGD was similar to that of the parental S pseudovirus (P = 0.21 by the 207

Wilcoxon matched-pairs signed rank test), and this recovered variant was 1.37-fold 208 more sensitive to vaccine-induced neutralization than the Lambda variant (P = 0.016 209 by the Wilcoxon matched-pairs signed rank test) (Figures 2B and S2D) . These 210 results suggest that Lambda S is highly infectious and resistant to vaccine-induced 211 humoral immunity, and the robust resistance of Lambda S to vaccine-induced 212 neutralization is determined by a 7-amino-acid deletion in the NTD. 213 214

Effect of consensus mutations in Lambda S on viral infectivity 215 We next examined six substitution mutations (G75V, T76I, L452Q, F490S, D614G  216 and T859N) and a deletion mutation (RSYLTPGD246-253N) of the Lambda variant 217 in the structure of the SARS-CoV-2 S protein. Structural analysis showed that the 218 three mutations, G75V, T76I and RSYLTPGD246-253N, are in the NTD (Figure 2C ), 219 and the RSYLTPGD246-253N mutation is located in a loop structure, which was 220 designated as loop 5 (residues 246-260) in a previous study (Chi et al., 2020) 221

( Figure 2D) . The G75V and T76I mutations are located at the flexible loop adjacent  222 to loop 5 ( Figure 2C) . The L452Q and F490S mutations are situated in the receptor-223 binding motif in the RBD (Figures 2C and 2D ), but neither residue is in the direct 224 contact with the ACE2 receptor ( Figure S2E) . The T859N mutation is in the heptad 225

repeat 1 of the S2 subunit ( Figure 2C ).

To investigate the effects of these seven consensus mutations in Lambda 227

S on viral infectivity and NAb sensitivity, we prepared viruses pseudotyped with 228 parental S-based derivatives that have mutations of the Lambda variant. Figure 2E  229 shows that the G75V mutation significantly reduces viral infectivity (P = 0.0004, by 230

Student's t test), while the T76I and GT75-76VI mutations significantly increase viral 231 infectivity (P = 0.0011, T75I versus parental; P = 0.012, GT75-76TI versus parental 232 by Student's t test). Additionally, 91.5% (1,746/1,908) of the Lambda variant 233 sequences had these two mutations and the phylogenetic tree of the Lambda variant 234

indicated that the variant harboring either G75V or T76I sporadically emerged during 235 the epidemic of the Lambda variant ( Figure S1A ). However, there were no viral 236 sequences harboring the G75V mutation without the T76I mutation ( Figure S1A ).

These findings suggest that T76I is a compensatory mutation to recover the 238 decreased infectivity by the G75V mutation. 239

Similar to the results from the experiment using pseudoviruses with 240

Lambda S and Lambda+N246-253RSYLTPGD (Figure 2A) , the insertion of the 241 RSYLTPGD246-253N mutation did not affect viral infectivity ( Figure 2E) . The 242

infectivity of the T859N mutation was also similar to that of the parental pseudovirus 243 ( Figure 2E ). When we focused on the effect of the mutations in the RBD, the L452Q 244 and L452Q/F490S mutations significantly increased viral infectivity (P = 0.0011, 245 L452Q versus parental; P = 0.0003, L452Q/F490S versus parental by Student's t 246 test), while the F490S mutation did not ( Figure 2E) . Additionally, the binding affinity 247 of the SARS-CoV-2 RBD to soluble ACE2 was significantly increased by the 248 insertion of the L452Q mutation but not the F490S mutation ( Figure 2F : P = 0.0004, 249 L452Q versus parental; P = 0.92, F490S versus parental; P = 0.0002, L452Q/F490S 250 versus parental by Student's t test). Taken together, these results suggest that the 251 T76I and L452Q mutations are responsible for the higher infectivity of Lambda S 252 ( Figure 2E ). The effect of each mutation was similar with different amounts of 253 pseudoviruses used and in the target cells without TMPRSS2 expression ( Figure  254 S2F).

Evasion of vaccine-induced cellular immunity induced by the L452Q mutation 257

Previous studies showed that the 9-mer peptide spanning the 448-456 residues of 258 the SARS-CoV-2 S protein (designated "NF9") is an immunodominant epitope 259

presented these cells with the NF9 peptide ( Table S5) . As shown in Figure S2G , ( Figures 2G and S2H) . These results suggest that the NF9 peptide is an 280 immunodominant epitope in HLA-A*24:02-positive vaccinated individuals and that 281 the L452Q mutation potentially results in evasion of HLA-A24-restricted cellular 282

immunity. 283 284

Evasion of vaccine-induced humoral immunity 285 We next assessed the sensitivity of these pseudoviruses with the mutated S proteins 286

to BNT162b2-induced antisera. As shown in Figure 2H , the G75V, T76I, GT75-76VI 287 and T859N mutations did not affect vaccine-induced neutralization. In contrast, the 288 RSYLTPGD246-253N mutant exhibited significant resistance to the vaccine-induced 289 neutralization ( Figure 2H : P = 0.027 by the Wilcoxon matched-pairs signed rank 290 test), which is relevant to the experiment with the S proteins of the Lambda variant 291 and the Lambda+N246-253RSYLTPGD derivative ( Figure 2B ). Additionally, we 292

found that the L452Q and F490S mutations confer resistance to vaccine-induced 293 antisera ( Figure 2H ). The finding that the F490S mutation does not affect viral 294 infectivity ( Figure 2E ) but confers the resistance to the vaccine-induced antisera 295

( Figure 2H ) suggests that this mutant has acquired resistance to antiviral humoral 296 immunity. In contrast, the L452Q mutation not only increases viral infectivity ( Figure  297 2E) and affinity to ACE2 ( Figure 2F ) but also augments resistance to the vaccine-298

induced antiviral cellular ( Figure 2G ) and humoral immunities ( Figure 2H) , 299 suggesting that this mutation is critical for the viral dissemination in the human 300 population. 301 302

Effects of NTD-targeting monoclonal antibodies on Lambda variant infection 303

To further assess the effect of the mutations in Lambda S, particularly those in the 304 NTD, we used two monoclonal antibodies that target the NTD: an NTD-targeting 305

NAb 2J). Because a polyclonal antibody targeting the SARS-CoV-2 S protein detected 315 these mutants, similar to the parental S ( Figure S2I ), our results suggest that the 316 RSYLTPGD246-253N mutation critically affects the sensitivity to certain NAbs 317

targeting the NTD, such as the 4A8 antibody. 318

For the COV2-2490 antibody, flow cytometry analysis showed that this 319 antibody more efficiently detects the Lambda S than the parental S ( Figure 2K ). 320

Although this antibody enhanced the infectivities of all pseudoviruses tested ( Figure  321 2L), importantly, the infectivity of the Lambda S was more significantly enhanced 322 than that of the parental S ( Figure We revealed that Lambda S is more resistant to vaccine-induced antiviral humoral 343 immunity (Figures 2B and 2H ) as well as an NTD-targeting NAb ( Figure 2J ) and 344 that the RSYLTPGD246-253N mutation is responsible for NAb resistance. 345

Additionally, the sensitivity of Lambda S to EAb was higher than that of the parental 346 S and was also attributed to the multiple mutations in the NTD, including the 347 RSYLTPGD246-253N mutation ( Figure 2L) . shield the viral particles from NAbs, we hypothesized that this property of Lambda S 358 is attributed to the nascent N-glycan conferred by the RSYLTPGD246-253N 359 mutation. To address this possibility, we prepared two Lambda S derivatives, N246A 360 and N246Q, which abolished the NLGS ( Figure 3A) . We also prepared two parental 361 S RSYLTPGD246-253N mutant-based derivatives, RSYLTPGD246-253A and 362

RSYLTPGD246-253Q ( Figure 3A ). As shown in Figure 3B , induced NAbs ( Figure 3C) . As in the cases of the Lambda S and the parental S 370 RSYLTPGD246-253N mutant (Figure 2I) , flow cytometry analysis showed that the 371 4A8 antibody faintly detected the NLGS-disrupted mutants on the cell surface 372

( Figure 3D ). Additionally, a neutralization assay revealed that the NLGS disruption 373 did not affect the sensitivity to the 4A8 antibody ( Figure 3E) . For an NTD-targeting 374

EAb, the COV2-2490 antibody, the detection on the cell surface by flow cytometry 375 ( Figure 3F ) and the enhancement of the pseudovirus infectivity ( Figure 3G) here, we showed that the Lambda variant shows increased infectivity and resistance 441 against antiviral immunity. These observations suggest that acquiring at least two 442 virological features, increased viral infectivity and evasion from antiviral immunity, is 443 pivotal for efficient spread and transmission in the human population. 444 We showed that the Lambda S is more resistant to the vaccine sera than 445 the parental S ( Figure 2B) . By the loss-of-function experiment, we also showed that 446 this immune resistance was canceled by the reversion of the NTD deletion 447 (RSYLTPGD246-253N mutation) in the context of the Lambda variant (Figure 2B) , 448 suggesting that the immune resistance of Lambda variant is mostly dependent 449 primarily on the RSYLTPGD246-253N mutation located in NTD. On the other hand, 450

in the gain-of-function experiment based on the parental S (Figure 2H) , the three 451 mutations detected in the Lambda variant, RSYLTPGD246-253N, L452Q and F490S, 452

can lead to the resistance to vaccine sera. The discrepancy between these two 453 experiments can be explained by the context of S proteins used as the backbone: 454 the gain-of-function experiment (Figure 2H ) suggests the potential of the 455 RSYLTPGD246-253N, L452Q and F490S mutations to confer resistance to vaccine 456 sera, when the backbone is parental S protein. However, the loss-of-function 457 experiment ( Figure 2B) suggests that the RSYLTPGD246-253N mutation 458 determines the resistance to vaccine sera, when the backbone is the Lambda S. 459

Because the Lambda S contains the other mutations compared to the parental S, 460 our data suggest that the resistance to the vaccine sera (i.e., polyclonal antibodies 461 elicited by vaccination) is dependent on the context of S protein sequence and/or 462 structure. Similarly, the context-dependent effect by the mutation insertion was also 463 observed in pseudovirus infection assay ( Figure 3B) and VOIs is essential to assess the risk of newly emerging SARS-CoV-2 variants in 528 the future. 529 530

Limitations of the Study 531

The experiments using pseudoviruses, we showed that the Lambda variant is more 532 infectious than the parental virus (Figure 2A) (Figures 2L and 3G) . Additionally, COV2-2490 gives more benefit to the Lambda 548 pseudovirus (Figures 2L and 3G) are summarized. The raw data are summarized in Table S3 . See also Figure S1 and Tables S1-S3. donor GV36-2) are shown in Figure S2H .

(H) Neutralization assay. A neutralization assay was performed using the 916 pseudoviruses used in Figure 2B and 18 BNT162b2-vaccinated sera as described 917

in STAR★METHODS. The raw data are shown in Figure S2B . percentages of infectivity compared to that of the virus without antibodies are shown. 925

Assays were performed in triplicate (except for H) or quadruplicate (H), and the mean 926 is shown with the SD. 927

In A, E, F, I and K, statistically significant differences (*, P < 0.05) versus parental S 928

were determined by Student's t test. 929

In A and E, vertical dashed lines indicate 100% (the value of parental S). 930

In B and H, statistically significant differences were determined by the Wilcoxon 931 matched-pairs signed rank test. The P values are indicated in the figure. 932

In G, statistically significant differences (*, P < 0.05) versus the NF9 peptide were 933 determined by the Wilcoxon matched-pairs signed rank test. 934

In I and K, vertical dashed lines indicate the MFIs of mock-transfected cells. 935

In J, statistically significant differences (*, P < 0.05) versus the value without the 936 antibody were determined by Student's t test. NS, no statistical significance. 937

In L, statistically significant differences versus the value without the antibody (*, P < 938 0.05) and the parental S (#, P < 0.05) were determined by Student's t test. 939

See also Figure S2 and Tables S4 and S5. Assays were performed in triplicate, and the mean is shown with the SD. 964

In B, statistically significant differences (*, P < 0. 

Vaccine breakthrough infections with SARS-CoV-2 variants

SARS-CoV-2 variants, spike mutations and immune escape

SARS-CoV-2 variants 681 B.1.351 and P.1 escape from neutralizing antibodies

Identification of cross-reactive CD8 + T cell receptors with 684 high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural 685 mutant variants

Generation and 688 transmission of inter-lineage recombinants in the SARS-CoV-2 pandemic

CoV-2 infections and incidence of presumptive B.1.427/B.1.429 variant among 693 healthcare personnel at a northern California academic medical center

Effectiveness of an inactivated 697 SARS-CoV-2 vaccine in Chile

HLA-B51 transgenic mice as recipients for production of polymorphic HLA-A, B-700 specific antibodies

SARS-CoV-2-specific CD8 + T 703 cell responses in convalescent COVID-19 individuals

MAFFT multiple sequence alignment software 705 version 7: improvements in performance and usability

Evidence for N-glycan shielding of antigenic 707 sites during evolution of human influenza A virus hemagglutinin

In vitro and in vivo functions of 711 SARS-CoV-2 infection-enhancing and neutralizing antibodies

The impact of mutations in SARS-CoV-2 spike on viral infectivity 715 and antigenicity

Removal of a single N-linked glycan in human 718 immunodeficiency virus type 1 gp120 results in an enhanced ability to induce 719 neutralizing antibody responses

BNT162b2-elicited neutralization of B.1.617 and 722 other SARS-CoV-2 variants

Neutralizing activity of BNT162b2-725 elicited serum

An infectivity-enhancing site on the 728 SARS-CoV-2 spike protein targeted by antibodies

An NTD supersite of attack

N-terminal domain antigenic 732 mapping reveals a site of vulnerability for SARS-CoV-2

Recurrent emergence

CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7

IQ-TREE 2: New models and efficient methods 739 for phylogenetic inference in the genomic era

SARS-CoV-2 B.1.617.2 Delta 742 variant replication and immune evasion

SARS-CoV-2 spike L452R variant 745 evades cellular immunity and increases infectivity

Efficient selection for high-747 expression transfectants with a novel eukaryotic vector

Vaccine breakthrough infections

CoV-2 variants

SARS-CoV-2 D614G spike mutation increases 752 entry efficiency with enhanced ACE2-binding affinity

Super-754 rapid quantitation of the production of HIV-1 harboring a luminescent peptide tag

Application of the restriction-free (RF) cloning for 757 multicomponents assembly

Mapping 760 Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor

Sensitivity of 765 infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Spike mutation D614G 769 alters SARS-CoV-2 fitness

Role of N-linked 771 glycans in a human immunodeficiency virus envelope glycoprotein: effects on 772 protein function and the neutralizing antibody response

A dynamic nomenclature proposal for SARS-CoV-2 775 lineages to assist genomic epidemiology

Vaccine breakthrough infections 777 with SARS-CoV-2 variants

A role for carbohydrates in 779 immune evasion in AIDS

SARS-CoV-2 spike P681R mutation enhances 782 and accelerates viral fusion

Vpu augments the initial burst phase of HIV-1 propagation and

2020) was used as the template, and 40 1102 homology models of the SARS-CoV-2 S of the Lambda variant were generated using 1103

Evaluation of 1104 the homology models was performed using PDF total scores and DOPE scores and 1105 the best model for Lambda S was selected

2021) and the Epsilon (B.1.427) variant (Motozono et al., 2021) were prepared in 1111 our previous studies. Plasmids expressing the S proteins of the Alpha (B.1.1.7), Beta 1112 (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Lambda (C.37) variants and the 1113 point mutants were generated by site-directed overlap extension PCR using pC-1114 SARS2-S D614G (Ozono et al., 2021) as the template and the following primers 1115 listed in Table S6. The resulting PCR fragment was digested with Acc65I or KpnI 1116 and NotI and inserted into the corresponding site of the pCAGGS plasmid

Cat# 6182) was digested with NotI 1119 and BamHI and the DNA fragment encoding Crimson or ZsGreen1 was inserted 1120 using a DNA ligation kit "Mighty Mix" (Takara, Cat# 6023)

Pseudovirus Assay

Pseudovirus assays were performed as previously described

Briefly, for pseudoviruses, lentivirus (HIV-1)-based, luciferase-1128 expressing reporter viruses pseudotyped with the SARS-CoV-2 S protein and its 1129 derivatives, HEK293T cells (1 × 10 6 cells) were cotransfected with 1 μg

The pseudoviruses prepared were stored at -80°C 1137 until use. For the experiment, HOS-ACE2 cells and HOS-ACE2/TMPRSS2 cells 1138 (10,000 cells/50 μl) were seeded in 96-well plates and infected with 100 μl of 1139 pseudoviruses prepared at 4 different doses. At two days postinfection, the infected 1140 cells were lysed with a One-Glo luciferase assay system (Promega, Cat# E6130), 1141 and the luminescent signal was measured using a CentroXS3 plate reader 1142

For competition assay (Figure S2C), pLVSIN-CMV Hyg vectors

Cat# 6182) encoding fluorescent proteins (Crimson or ZsGreen1) were used to 1146 prepare the pseudoviruses bearing Lambda S or Lambda+N246-253RSYLTPGD S

HEK293T cells were cotransfected with psPAX2-IN/HiBiT (800 ng

Lambda S expression plasmid (400 ng), and pLVSIN-CMV Hyg-Crimson (800 ng) or 1149 psPAX2-IN/HiBiT (800 ng), the Lambda+N246-253RSYLTPGD S expression 1150 plasmid (400 ng), and pLVSIN-CMV Hyg-ZsGreen1

000 cells/50 μl) were seeded in 96-well plates and 1152 infected with a Crimson-expressing reporter virus pseudotyped with Lambda S and 1153 a ZsGreen1-expressing reporter virus pseudotyped with Lambda+N246-1154 253RSYLTPGD S (at 2,000 ng p24 antigen each)

Antibody Treatment

Antibody treatment for neutralization and infectivity enhancement was performed as 1162 previously described

2020) or the EAb clone COV2-2490 1167 (Liu et al., 2021c) at 37°C for 1 h. Pseudoviruses without sera/antibodies were 1168 included as controls. Then, an 80 μl mixture of pseudovirus and sera/antibodies was 1169 added to HOS-ACE2/TMPRSS2 cells (10,000 cells/50 μl) in a 96-well white plate, 1170 and the luminescence was measured as described above (see

Cat# 99845) 1178 (Zahradnik et al., 2021a) was transfected into Expi293 cells using an ExpiFectamine 1179 293 transfection kit (Thermo Fisher Scientific, Cat# A14525) according to the 1180 manufacturer's protocol. Expression enhancer was added 16 h posttransfection and 1181 the expression continued for an additional three days. Subsequently, the culture 1182 medium was harvested, centrifuged, filtered through a 0.45-µm pore size filter 1183

Cat# 17-5255-01) using a ÄKTA pure 1185 chromatography system (Cytiva). The purified protein was concentrated in PBS by 1186 using an Ultracel-3 regenerated cellulose membrane (Merck, Cat# UFC900324)

The batch-to-batch reproducibility was assessed using a Tycho NT

Briefly, the 1191 plasmid pJYDC1 (Addgene, Cat# 162458) (Zahradnik et al., 2021b) encoding the 1192 SARS-CoV-2 S RBD (residues 336-528) (pJYDC1-RBD) (Zahradnik et al., 2021a) 1193 was modified by the restriction enzyme-free cloning procedure (Peleg and Unger

pCTCON_seq_F: 5'-GCA GCC CCA TAA ACA 1202 CAC AGT AT-3' was used for sequencing. The PCR products were integrated into 1203 pJYDC1 by integration PCR as previously described

Single colony cultures grown in 1 ml of liquid SD-CAA medium 1212 (Zahradnik et al., 2021a) overnight at 30°C (220 rpm), were used to inoculate 1213 expression 1/9 medium (Zahradnik et al., 2021a) with 1 nM bilirubin (Sigma-Aldrich, 1214 Cat# 14370-1G). The cells, washed with PBS-B buffer [PBS supplemented with 1215 bovine serum albumin (1 g/l)], were aliquoted into solutions (1-100 ml

Cat# 43-50020-03), after which the binding 1221 signal of CF640R-labeled human ACE2 protein (residues 18-740) attached to yeasts 1222 was analyzed using an S3e Cell Sorter device

Activation-Induced Marker Assay 1228

Briefly, expansion of antigen-specific human CD8 + T cells and the 1230 analysis of the surface expression levels of the activation markers CD25 and CD137 1231 were performed as previously described

Cat# 11875101) 1235 containing 10% FCS and 30 U/ml recombinant human IL-2 (Peprotec, Cat# 200-02) 1236 for 10-14 days. The in vitro expanded CD8 + T cells (i.e., CTL lines) were restimulated 1237 with or without the NF9 peptide. After incubation at 37°C for 24 h, the cells were 1238 washed, and surface proteins (CD3, CD8, CD14, CD19, CD25 and CD137) were 1239 stained with the antibodies listed in Key Resources Table. Dead cells were stained 1240 with 7-aminoactinomycin D (Biolegend, Cat# 420404)

Intracellular Cytokine Staining 1247

Briefly, C1R-A2402 cells were pulsed with or without the NF9 peptide or 1249 its derivatives [the NF9-L452Q peptide (NYNYQYRLF, L5Q in NF9) and the NF9-1250 L452Q peptide (NYNYRYRLF, L5R in NF9); synthesized by Scrum, Inc.] at 1251 concentrations from 0.1 to 10 nM at 37°C for 1 h. The cells were washed twice with 1252 PBS, mixed with the CTL lines generated from vaccinated or nonvaccinated donors 1253 (see above) and incubated with RPMI 1640 medium (Thermo Fisher Scientific, Cat# 1254 11875101) containing 10% FCS and 5 μg/ml brefeldin A (Sigma-Aldrich, Cat# 1255 B7651) in a 96-well U plate at 37°C for 5 h. The cells were washed, and surface 1256 proteins (CD3, CD8, CD14 and CD19) were stained with the antibodies listed in Key 1257 Resources Table

After incubation at room temperature for 30 min, the cells were 1262 washed, and the levels of protein expression were analyzed by flow cytometry using 1263 a FACSCanto II (BD Biosciences) followed by analysis using FlowJo software

Briefly, the HEK293T cells transfected with the plasmids 1269 for the expression of S derivatives were washed with PBS and incubated with 4A8 1270 antibody

Thermo Fisher Scientific; Cat# PA5-112048) at 1272 4°C for 30 min. The cells were washed with PBS twice and stained with an APC-1273 conjugated anti-human IgG monoclonal antibody (Biolegend; Cat #410712

Alexa Fluor 647-conjugated anti-rabbit IgG antibody

The cells stained with the fluorescent-labeled antibodies 1276 were washed with PBS twice and fixed with 4% formaldehyde (Nacalai Tesque

QUANTIFICATION AND STATISTICAL ANALYSIS 1281 Data analyses were performed using Prism 9

Fetal calf serum (FCS) Sigma-Aldrich Cat# 172012-500ML

All unique reagents generated in this study are listed in the Key Resources Table  999 and available from the Lead Contact with a completed Materials Transfer Agreement. 1000 1001

The data reported in this paper will be shared by the lead contact upon request. 1003 This paper does not report original code. 1004Any additional information required to reanalyze the data reported in this paper is 1005 available from the lead contact upon request. We aligned entire genome sequences by using the FFT-NS-1 program in MAFFT 1064 suite v7.407 (Katoh and Standley, 2013) and deleted gapped regions in the 5' and 10653' regions. We constructed a phylogenetic tree using IQ-TREE 2 v2.1.3 software 1066 (Minh et al., 2020) with 1,000 bootstraps ( Figure S1A ). The GTR+G substitution 1067 model is utilized based on the BIC criterion. We found that several sequences 1068 without the RSYLTPGD246-253N mutation also clustered with the genomes carrying 1069 the RSYLTPGD246-253N mutation (Figure S1A) , which could be due to reversible 1070 mutation(s) and/or recombination (Jackson et al., 2021) . Thus, these sequences 1071were excluded from further analysis. 1072To estimate the emergence time of the Lambda variant (C.37 lineage), we 1073 collected all Lambda sequences carrying the RSYLTPGD246-253N mutation that 1074were sampled in 2020 (2 sequences) and randomly sampled 100 sequences in 2021. 1075 We also added the following 4 SARS-CoV-2 genomes as the outgroup: strain 1076Wuhan-Hu- lineage, although they were previously categorized as the C.37 lineage. We carefully 1081 examined these two sequences and found that they could be used as a sister group 1082 of the C.37 lineage. EPI_ISL_1534645 does not contain any typical mutations in the 1083 S protein, but it is close to the genuine Lambda variant ( Figure S1A) . Therefore, we 1084 included these four sequences in the analysis. We conducted Bayesian tip-dating 1085 analysis using BEAST v1.10.4 (Suchard et al., 2018). We used the GTR+Gamma 1086 model for the nucleotide substitution model. For the assumption of rate variations, 1087we applied an uncorrelated relaxed clock, assuming that the distribution of rates 1088 followed a gamma distribution. We carefully reviewed the effective sample size of 1089 each parameter and confirmed that all were > 200. The time to the most recent 1090 common ancestor of the genuine Lambda variants was estimated to be 2020.7585 1091 (95% HPD, 2020.245-2020.8525). A timetree was generated using TreeAnnotator 1092 software in the BEAST package and visualized by using FigTree v1.4.4 ( Figure 1C  1093 and Figure S1B) . Reconstruction of the population history, namely, the change in 1094 effective population size over time (Figure 1D) , was conducted by a Bayesian 1095 skyline plot using the same software and parameter settings with the Lambda 1096 sequences as noted in the tip-dating analysis. 1097 1098Protein Structure Homology Model 1099All protein structural analyses were performed using Discovery Studio 2021 1100 (Dassault Systèmes BIOVIA). In Figures 2C and 2D Table S6 This study N/A